Opinion
Video
Improving Clinician Awareness and Adoption of Molecular Testing
Author(s):
A panelist discusses how guidelines from organizations like the National Comprehensive Cancer Network (NCCN) can improve clinician awareness and adoption of molecular testing in community oncology settings while acknowledging that some effective treatments work across patient populations without requiring biomarker stratification.
Video content above is prompted by the following:
Improving Clinician Awareness and Adoption in Community Settings
Strategies to improve molecular testing adoption in community oncology include the following:
- Enhanced educational initiatives for physicians
- Greater reliance on guidelines like NCCN, which provide flexibility in clinical application
- Improved reimbursement policies that incentivize evidence-based care
- Recognition that although biomarker-directed therapy is important, treatments that work across all patients (biomarker-agnostic) remain valuable
Recent examples of non–biomarker-directed advances include relacorilant (cortisol blocker) with nab-paclitaxel showing improved progression-free survival and overall survival in platinum-resistant ovarian cancer, and tisotumab vedotin (targeting tissue factor) in cervical cancer.
Collaboration between academic and community settings, participation in clinical research, and tissue collection for biomarker discovery remain essential for continued progress in treatment personalization.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
